Podcast: This Week in Managed Care&amp;mdash;New Hypertension Guidelines, and Other Health News

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

AAP’s 2026 immunization schedule continues protection against 18 diseases as the CDC reduces its recommendations to 11.

ICE Presence in Minnesota Health Care Settings Threatens Access to Essential Medical Care

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

Minnesota clinicians say ICE enforcement near hospitals and clinics is discouraging patients from seeking critical medical care. | Image Credit: @TadaImages-Adobestock.jpeg

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Minnesota physicians warn ICE activity in hospitals and clinics is deterring care, undermining patient safety, and worsening health outcomes.

January 20th 2026

ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

ACE inhibitors show promise in lowering mortality for IPF, suggesting new therapeutic potential for an existing medication. | Image credit: Елена Бутусова-stockk.adobe.com

5 Ongoing Phase 3 Trials in Hematologic Malignancies

ACE inhibitors may improve survival in IPF patients, highlighting potential repurposing of a common cardiovascular drug.

Hematologic disorder | Image Credit: ©Orawan-stock.adobe.com

AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule

Ongoing phase 3 trials target improved therapies for hematologic malignancies, focusing on CLL, multiple myeloma, and pediatric leukemia outcomes.

Related Content

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

AAP’s 2026 immunization schedule continues protection against 18 diseases as the CDC reduces its recommendations to 11.

ICE Presence in Minnesota Health Care Settings Threatens Access to Essential Medical Care

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Minnesota physicians warn ICE activity in hospitals and clinics is deterring care, undermining patient safety, and worsening health outcomes.

January 20th 2026

ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

5 Ongoing Phase 3 Trials in Hematologic Malignancies

ACE inhibitors may improve survival in IPF patients, highlighting potential repurposing of a common cardiovascular drug.